More on BMY

- Summary
- Chart
- Profile
- Historical


- Earnings (-13.3% Growth)
- Ratings (4.8 Score)
- Holders
- Dividends (2.2% Yield)
- FDA Archive


Income Statement
Balance Sheet
Cash Flow Statement

Upcoming Events

- Earnings (1/27/16 *Est.)


- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks

BMY Balance Sheet

Click line-items for a historical chart and %
Current Assets:
Cash and cash equivalents 3.98B
Marketable securities 1.44B
Receivables 3.91B
Inventories 1.13B
Deferred income taxes 1.73B
Prepaid expenses and other 529M
Total Current Assets 12.93B
Property, plant and equipment 4.25B
Goodwill 6.95B
Other intangible assets 1.54B
Deferred income taxes 719M
Marketable securities 4.63B
Other assets 762M
Total Assets 31.78B
Current Liabilities:
Short-term borrowings 642M
Accounts payable 1.25B
Accrued expenses 2.33B
Deferred income 963M
Accrued rebates and returns 1.16B
U.S. and foreign income taxes payable 179M
Dividends payable 636M
Total Current Liabilities 7.16B
Pension, postretirement, and postemployment liabilities 902M
Deferred income 630M
U.S. and foreign income taxes payable 716M
Other liabilities 468M
Long-term debt 6.63B
Total Liabilities 16.51B
Commitments and contingencies (Note 14) 0
Bristol-Myers Squibb Company Shareholders' Equity:
Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 5,268 in 2011 and 5,269 in 2010, liquidation value of $50 per share 0
Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.2 billion issued in both 2011 and 2010 221M
Capital in excess of par value of stock 1.41B
Accumulated other comprehensive loss -2.4B
Retained earnings 32.45B
Less cost of treasury stock - 500 million common shares in 2011 and 501 million in 2010 -16.61B
Total Bristol-Myers Squibb Company Shareholders' Equity 15.08B
Noncontrolling interest 194M
Total Equity 15.27B
Total Liabilities and Equity 31.78B